Table 6.
Subgroup analysis of the results.
| Indication | Number of studies | SURCA |
|---|---|---|
| SE control rate | ||
| Children | 12 | PHB(95.5%) > VPA(42.1) > LEV(41.7) > PHT(20.2) > FPHT(20.2) |
| Adult | 7 | PHB(99.3%) > LEV(55.6) > VPA(31.8) > PHT(14.9) > FPHT(10.8) |
| Elderly | 2 | LEV(70.9%) > VPA(46.9) > PHT(30.9) |
| Mixed | 2 | VPA(77.9%) > LEV(55.9) > PHT(25.5) |
| Epilepsy recurrence rate | ||
| Children | 7 | VPA(80.5%) > LEV(45.9) > PHT(40.9) > PHB(33.9) > FPHT(16.9) |
| Adult | 2 | |
| Mixed | 2 | VPA(75.5%) > LEV(55.6) > PHT(22.9) |
| Rate of further AED treatment needed | ||
| Children | 5 | VPA(78.9%) > LEV(55.9) > PHT(23.2) |
| Incidence of ADEs | ||
| Children | 10 | LEV(93.6) > PHT(52.3) > VPA(42.6%) > PHB(10.6) > FPHT(8.5) |
| Adult | 7 | VPA(92.2%) > PHB(72.6) > LEV(40.3) > PHT(25.6) > FPHT(18.9) |
| Elderly | 2 | LEV(75.6%) > VPA(69.2) > PHT(8.3) |
| Mixed | 2 | VPA(82.6%) > LEV(66.9) > PHT(10.3) |
ADE = adverse drug events, AED = antiepileptic drugs, FPHT = fosphenytoin, LEV = levetiracetam, PHB = phenobarbital, PHT = phenytoin, VPA = valproic acid, SE = status epilepticus, SURCA = surface under the cumulative ranking curve.